On 4 June, Anavex Life Sciences Corp - a clinical-stage biopharmaceutical company developing therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) - announced that is has received regulatory approval from Health Canada and Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) to expand its Phase II/III clinical trial for the treatment of AD into Canada and the UK.
The Phase II/III trial is a double-blind, randomised and placebo-controlled study currently underway in Australia, with more than 50% of the 450 research participants enrolled. It is aiming to evaluate the safety and efficacy of ANAVEX 2-73 in people with early AD.
